HK1044472A1 - 用於心血管適症的回腸胆汁酸轉運抑制劑和烟酸類衍生物的聯合形式 - Google Patents

用於心血管適症的回腸胆汁酸轉運抑制劑和烟酸類衍生物的聯合形式

Info

Publication number
HK1044472A1
HK1044472A1 HK02106126.2A HK02106126A HK1044472A1 HK 1044472 A1 HK1044472 A1 HK 1044472A1 HK 02106126 A HK02106126 A HK 02106126A HK 1044472 A1 HK1044472 A1 HK 1044472A1
Authority
HK
Hong Kong
Prior art keywords
combinations
transport inhibitors
ileal bile
cardiovascular indications
acid derivatives
Prior art date
Application number
HK02106126.2A
Other languages
English (en)
Inventor
T Keller Bradley
C Glenn Kevin
T Connolly Daniel
Original Assignee
G‧D‧瑟爾有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1044472(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G‧D‧瑟爾有限公司 filed Critical G‧D‧瑟爾有限公司
Publication of HK1044472A1 publication Critical patent/HK1044472A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HK02106126.2A 1998-12-23 2002-08-21 用於心血管適症的回腸胆汁酸轉運抑制劑和烟酸類衍生物的聯合形式 HK1044472A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11395598P 1998-12-23 1998-12-23
US14255099P 1999-07-07 1999-07-07
PCT/US1999/027950 WO2000038729A1 (en) 1998-12-23 1999-12-17 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications

Publications (1)

Publication Number Publication Date
HK1044472A1 true HK1044472A1 (zh) 2002-10-25

Family

ID=26811675

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106126.2A HK1044472A1 (zh) 1998-12-23 2002-08-21 用於心血管適症的回腸胆汁酸轉運抑制劑和烟酸類衍生物的聯合形式

Country Status (25)

Country Link
US (1) US20030125316A1 (zh)
EP (1) EP1140191B1 (zh)
JP (1) JP2002533415A (zh)
KR (1) KR20010102963A (zh)
CN (1) CN1338946A (zh)
AR (1) AR037806A1 (zh)
AT (1) ATE226448T1 (zh)
AU (1) AU776952B2 (zh)
BR (1) BR9916567A (zh)
CA (1) CA2356664A1 (zh)
CZ (1) CZ20012343A3 (zh)
DE (1) DE69903661T2 (zh)
DK (1) DK1140191T3 (zh)
EA (1) EA005030B1 (zh)
ES (1) ES2188285T3 (zh)
HK (1) HK1044472A1 (zh)
HU (1) HUP0104593A3 (zh)
IL (1) IL143938A0 (zh)
MX (1) MXPA01006467A (zh)
MY (1) MY121399A (zh)
NO (1) NO20013160L (zh)
NZ (1) NZ512533A (zh)
PL (1) PL348581A1 (zh)
PT (1) PT1140191E (zh)
WO (1) WO2000038729A1 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1582151A (zh) 2001-09-08 2005-02-16 阿斯特拉曾尼卡有限公司 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
CA2815698C (en) * 2010-11-08 2019-04-30 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
SI2637668T1 (sl) 2010-11-08 2016-11-30 Albiero Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
CA2876540C (en) * 2012-06-15 2022-11-29 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
WO2019245449A1 (en) 2018-06-20 2019-12-26 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
AU2020218908A1 (en) 2019-02-06 2021-08-26 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
DK1140191T3 (da) 2003-02-24
PL348581A1 (en) 2002-06-03
EP1140191A1 (en) 2001-10-10
WO2000038729A1 (en) 2000-07-06
AR037806A1 (es) 2004-12-09
DE69903661T2 (de) 2003-07-03
EA200100703A1 (ru) 2001-12-24
KR20010102963A (ko) 2001-11-17
JP2002533415A (ja) 2002-10-08
CN1338946A (zh) 2002-03-06
HUP0104593A3 (en) 2004-10-28
IL143938A0 (en) 2002-04-21
MY121399A (en) 2006-01-28
BR9916567A (pt) 2001-12-11
US20030125316A1 (en) 2003-07-03
MXPA01006467A (es) 2004-03-10
ATE226448T1 (de) 2002-11-15
DE69903661D1 (de) 2002-11-28
CA2356664A1 (en) 2000-07-06
AU2348100A (en) 2000-07-31
EP1140191B1 (en) 2002-10-23
EA005030B1 (ru) 2004-10-28
NO20013160L (no) 2001-08-21
PT1140191E (pt) 2003-01-31
HUP0104593A2 (hu) 2002-03-28
NZ512533A (en) 2004-02-27
NO20013160D0 (no) 2001-06-22
ES2188285T3 (es) 2003-06-16
AU776952B2 (en) 2004-09-30
CZ20012343A3 (cs) 2001-12-12

Similar Documents

Publication Publication Date Title
PL348581A1 (en) Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
IL143947A0 (en) Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
HUP0104745A3 (en) Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
HUP0201972A2 (en) Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
NO20010016D0 (no) Benzotiepiner med aktivitet som inhibitorer for ileal gallesyretransport og opptak av taurocholat
HUP9903047A3 (en) Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
EP1368509A4 (en) ANTI-CORROSION COMPOSITION AND METHOD FOR METALS
IL144716A0 (en) Novel 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
HK1053054A1 (zh) 5型和3型17b-羥類固醇脫氫酶抑制劑及其使用方法
HUP0003824A2 (en) Method and compositions for preventing corrosion of metal substrates
EP1253207A4 (en) PROCESS AND EQUIPMENT FOR MELTING METAL
HK1038865A1 (zh) RAS-法呢基轉移酶抑制物與硫丁基醚-7-β-環糊精或2-羥基丙基-β-環糊精的複合物及方法
PL354349A1 (en) Method and apparatus for electro-deposition of metal
EP1065281A4 (en) METHOD FOR SEARCHING FOR STEROID SULFATASE INHIBITORS
SI1091953T1 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
NO984146D0 (no) Nye benzotiepiner med aktivitet som inhibitorer av ileal gallesyretransport og taurocholatopptak
IL129677A0 (en) Method and system of cross-marketing utilizing electronic coupons
AU2003201377A1 (en) Novel Intermediates and processes for the preparation of benzothiepineshaving activity as inhibitors of ileal bile acid transport and taurocholate uptake
EP1234294A4 (en) METHOD FOR DETERMINING ZODIAC SIGNS